Vanessa Lewinger Dunleavy, ARNP

Vanessa Dunleavy practices at Swedish Medical Center -First Hill in Seattle, Washington.

Vanessa Dunleavy's NPI, 1467980276, was assigned on May 24, 2017. Vanessa Dunleavy holds Washington license AP60741542.

Vanessa Dunleavy's primary practice is Swedish Medical Center -First Hill, at 747 Broadway, Seattle, WA 98122 in King County. The practice phone is (206) 386-6000.

Vanessa Dunleavy's primary practice is Swedish Medical Center -First Hill in Seattle, Washington. The medical group on file is Swedish Health Services. Dmand AI also links Vanessa Dunleavy to 1 more group practice or clinic, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Vanessa Dunleavy practices. Vendor and product names are available with a free account.

Nurse practitioner is Vanessa Dunleavy's primary specialty in the NPI Registry, under taxonomy code 363L00000X. Vanessa Dunleavy is licensed in Washington.

CMS data shows 176 Medicare services from Vanessa Dunleavy across 3 procedure codes in 2024, for 127 Medicare patients. Medicare paid $9,490 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 127 Medicare patients who saw Vanessa Dunleavy in 2024. The largest group is 65 to 74, with 58 patients. 64% of them have high blood pressure, and 61% have high cholesterol. Their average risk score is 2.17, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

In 2024, Vanessa Dunleavy wrote 174 Medicare Part D claims for 61 patients. 68% of them were for generic drugs. CMS names the drug for 96 of them, across 5 drugs with 11 or more claims each, at $621,007 in total drug cost.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 87 out of 100 for Vanessa Dunleavy for performance year 2024, reported as part of a group. Vanessa Dunleavy accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

CMS Open Payments shows 34 general payments to Vanessa Dunleavy from 3 drug and device companies in 2024. Speaker and faculty fees make up the largest share, 73% of the total. Abbvie Inc. paid the most, $9,791.